Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors.

F.E. Stuurman; E.E. Voest; A. Awada; P.O. Witteveen; T. Bergeland; P.A. Hals; W. Rasch; J.H.M. Schellens; A. Hendlisz

doi:10.1007/s10637-013-9925-z.

Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors.

F.E. Stuurman
, E.E. Voest
, A. Awada
, P.O. Witteveen
, T. Bergeland
, P.A. Hals
, W. Rasch
, J.H.M. Schellens
, A. Hendlisz

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	959-966
Number of pages	8
Journal	Investigational New Drugs
Volume	31
Issue number	4
DOIs	https://doi.org/10.1007/s10637-013-9925-z.
Publication status	Published - 2013

Access to Document

10.1007/s10637-013-9925-z.

Cite this

@article{bf3ec8c5161844d1a17f53838de48a81,

title = "Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors.",

author = "F.E. Stuurman and E.E. Voest and A. Awada and P.O. Witteveen and T. Bergeland and P.A. Hals and W. Rasch and J.H.M. Schellens and A. Hendlisz",

year = "2013",

doi = "10.1007/s10637-013-9925-z.",

language = "English",

volume = "31",

pages = "959--966",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "4",

}

TY - JOUR

T1 - Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors.

AU - Stuurman, F.E.

AU - Voest, E.E.

AU - Awada, A.

AU - Witteveen, P.O.

AU - Bergeland, T.

AU - Hals, P.A.

AU - Rasch, W.

AU - Schellens, J.H.M.

AU - Hendlisz, A.

PY - 2013

Y1 - 2013

U2 - 10.1007/s10637-013-9925-z.

DO - 10.1007/s10637-013-9925-z.

M3 - Article

SN - 0167-6997

VL - 31

SP - 959

EP - 966

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 4

ER -